1. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. (22nd January 2022) Authors: Castro, Januario E.; Lengerke-Diaz, Paula A.; Velez Lujan, Juliana; Choi, Michael Y.; Moreno-Cortes, Eider F.; Forero, Jose V.; Garcia-Robledo, Juan Esteban; Jacobs, Chaja; McCarthy, Colin; Heinen, Alaina; Amaya-Chanaga, Carlos I.; Kipps, Thomas J. Other Names: Matutes Estella M. Academic Editor. Journal: Advances in hematology Issue: Volume 2022(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗